Sandbox Reserved 425: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
Student (talk | contribs)
students
33,923 edits
No edit summary
Student (talk | contribs)
students
33,923 edits
No edit summary
Line 53: Line 53:
==Quiz Question 1==
==Quiz Question 1==


Ponatinib is unique in it's ability to bind to the resistant BCR-ALB because of it's preference to the DFG-out conformation. If a competitive inhibitor was created to prevent Ponatinib from binding to BCR-ALB to further the resistance, what specific structures would the inhibitor need to posses? Consider the unique binding methods of Ponatinib and the <scene name='48/483882/Active_sitezoom/1'>DFG-out</scene>  conformation.  
Ponatinib is unique in it's ability to bind to the mutated BCR-ALB because of it's preference to shift to the DFG-out conformation. If a competitive inhibitor was created to prevent Ponatinib from binding to BCR-ALB to further its drug resistance, what specific structure characteristics would the inhibitor need to posses? Consider the unique binding methods of Ponatinib and the <scene name='48/483882/Active_sitezoom/1'>DFG-out</scene>  conformation.  
   
   
a. A small, fully conjugated aromatic system with no electronegative substituents, to prevent unwanted hydrogen bonding.  
a. A small, fully conjugated aromatic system with no electronegative substituents, to prevent unwanted hydrogen bonding.  
Retrieved from "https://proteopedia.org/Sandbox_Reserved_425"